BMO Capital Reiterates Outperform Rating on Pfizer (PFE) as Early-Stage Oral GLP-1s Show Promise in T2D & Obesity
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $65.00 price target on Pfizer (NYSE: PFE) following interesting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
